CD23 positive patients with t(11;14) translocationhave thrombocytopenia with lower overall survivalcompared with CD23 negative patients (26).Although the role of CD23 marker in plasma cell leukemiawith the t(11;14) translocation is not known,it may be considered a reasonable therapeutic for anovel target therapy (27). This evidence concerns the gene FCER2 and Thrombocytopenia.